(Q37871213)

English

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

scientific article published on 02 May 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

Pieter E Postmus

0 references

author name string

E Felip

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

C Gridelli

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

P Baas

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

R Rosell

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

R Stahel

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Panel Members

6

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

publication date

2 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1507-1519

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

PIK3CA mutations and copy number gains in human lung cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Long-term survival expectations of cancer patients in Europe in 2000-2002.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

The role of chemotherapy in the treatment of patients with brain metastases from solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR150

21 January 2018

Identifiers

10.1093/ANNONC/MDR150

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37871213&oldid=2109169142"